VEGFA and age-related macular degeneration: Despite the emergence of anti-VEGF agents to treat the wet form of late AMD, and the recently FDA-approved pegcetacoplan, a complement C3 inhibitor, to slow the progression of the dry form of late AMD, there are no approved drugs available to prevent the development of wet or dry AMD.